{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:02:36Z","timestamp":1778900556748,"version":"3.51.4"},"reference-count":15,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","dmidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.diagmicrobio.2016.01.008","type":"journal-article","created":{"date-parts":[[2016,1,12]],"date-time":"2016-01-12T02:31:32Z","timestamp":1452565892000},"page":"77-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["In vitro activity of tedizolid against staphylococci isolated from prosthetic joint infections"],"prefix":"10.1016","volume":"85","author":[{"given":"Suzannah M.","family":"Schmidt-Malan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerryl E.","family":"Greenwood Quaintance","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa J.","family":"Karau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2016.01.008_bb0005","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1128\/AAC.01653-09","article-title":"Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain","volume":"54","author":"Betriu","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.01.008_bb0010","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1128\/AAC.01569-09","article-title":"Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges","volume":"54","author":"Brown","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.01.008_bb0015","series-title":"National hospital discharge survey: 2010 table, procedures by selected patient characteristics","author":"Centers for Disease Control and Prevention (CDC)","year":"2010"},{"key":"10.1016\/j.diagmicrobio.2016.01.008_bb0020","series-title":"CLSI document M07-A10","article-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u2014tenth edition","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2015"},{"key":"10.1016\/j.diagmicrobio.2016.01.008_bb0025","series-title":"Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement M100-S26","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2016"},{"key":"10.1016\/j.diagmicrobio.2016.01.008_bb0030","first-page":"E1","article-title":"The perpetual challenge of antimicrobial resistance","author":"Fauci","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.diagmicrobio.2016.01.008_bb0035","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrmicro821","article-title":"Bacterial biofilms: from the natural environment to infectious diseases","volume":"2","author":"Hall-Stoodley","year":"2004","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.diagmicrobio.2016.01.008_bb0040","first-page":"1","article-title":"TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens","volume":"SQ1","author":"Jones","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.01.008_bb0045","doi-asserted-by":"crossref","first-page":"780","DOI":"10.2106\/JBJS.F.00222","article-title":"Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030","volume":"89","author":"Kurtz","year":"2007","journal-title":"J Bone Joint Surg Am"},{"issue":"61\u201365","key":"10.1016\/j.diagmicrobio.2016.01.008_bb0050","article-title":"Economic burden of periprosthetic joint infection in the United States","volume":"27","author":"Kurtz","year":"2012","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.diagmicrobio.2016.01.008_bb0055","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.diagmicrobio.2014.08.011","article-title":"Results of the Surveillance of Tedizolid Activity and Resistance Program: in vitro susceptibility of Gram-positive pathogens collected in 2011 and 2012 from the United States and Europe","volume":"81","author":"Sahm","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2016.01.008_bb0100","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1128\/AAC.00228-09","article-title":"In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent","volume":"53","author":"Schaadt","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.01.008_bb0060","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1128\/CMR.00111-13","article-title":"Prosthetic joint infection","volume":"27","author":"Tande","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.diagmicrobio.2016.01.008_bb0065","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1128\/AAC.00274-13","article-title":"Activity of tedizolid (TR-700) against well-characterized methicillin-resistant Staphylococcus aureus strains of diverse epidemiological origins","volume":"57","author":"Thomson","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2016.01.008_bb0070","first-page":"555","article-title":"Tedizolid Phosphate (Sivextro): a second-generation oxazolidinone to treat acute bacterial skin and skin structure infections","volume":"39","author":"Wong","year":"2014","journal-title":"Pharm Ther"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889316000092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889316000092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T07:24:08Z","timestamp":1537082648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889316000092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0732889316000092"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2016.01.008","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of tedizolid against staphylococci isolated from prosthetic joint infections","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2016.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}